Comparative Pharmacology
Head-to-head clinical analysis: ALTABAX versus SSD AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTABAX versus SSD AF.
ALTABAX vs SSD AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to bacterial DNA and cell wall components, causing disruption of cellular respiration and DNA replication. It also inhibits bacterial cell wall synthesis via the sulfadiazine component.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
Apply a thin layer topically once or twice daily to affected area.
None Documented
None Documented
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Terminal elimination half-life is 6–8 hours; clinically, this supports twice-daily dosing in most patients.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Renal: ~10% as unchanged drug; biliary/fecal: ~90% as metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic